David Denton - Pfizer Chief VP
| PFE Stock | EUR 24.07 0.01 0.04% |
Insider
David Denton is Chief VP of Pfizer Inc
| Age | 58 |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
David Denton Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Denton against Pfizer stock is an integral part of due diligence when investing in Pfizer. David Denton insider activity provides valuable insight into whether Pfizer is net buyers or sellers over its current business cycle. Note, Pfizer insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pfizer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Denton over six months ago Acquisition by David Denton of 2055 shares of Cintas at 759.63 subject to Rule 16b-3 |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1287 % which means that it generated a profit of $0.1287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3622 %, meaning that it generated $0.3622 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Reynders | Moderna | N/A | |
| Ken Patel | The Procter Gamble | N/A | |
| Matthew Janzaruk | The Procter Gamble | 49 | |
| Noubar Afeyan | Moderna | 60 | |
| Ray Jordan | Moderna | N/A | |
| Paul Sagan | Moderna | 59 | |
| Brett Iversen | Microsoft | N/A | |
| Stephen MD | Moderna | 47 | |
| Satya Nadella | Microsoft | 56 | |
| Robert Decker | Johnson Johnson | 51 | |
| Christopher Capossela | Microsoft | 53 | |
| Frank Shaw | Microsoft | N/A | |
| Melissa Moore | Moderna | N/A | |
| Jerh Collins | Moderna | N/A | |
| Elizabeth Tallett | Moderna | 70 | |
| Tal Zaks | Moderna | 53 | |
| Israel Ruiz | Moderna | 47 | |
| Jessica Moore | Johnson Johnson | N/A | |
| James Mock | Moderna | 46 | |
| Christopher Young | Microsoft | 51 | |
| Amy Hood | Microsoft | 51 | |
Management Performance
| Return On Equity | 0.36 | |||
| Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President - Global Established Pharma Business | ||
| Jennifer Damico, Controller VP | ||
| Christopher CFA, VP Officer | ||
| DVM DVM, Chairman CEO | ||
| Frank DAmelio, CFO, Executive Vice President - Business Operations | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
| Angela Hwang, Group President - Pfizer Essential Health | ||
| Mikael MD, Dev Research | ||
| David Denton, Chief VP |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.36 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 276.06 B | |||
| Shares Outstanding | 5.62 B | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 71.00 % | |||
| Price To Earning | 16.17 X | |||
| Price To Book | 3.13 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Pfizer Stock
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.